Literature DB >> 23913528

Folic acid fortification and the birth prevalence of congenital heart defect cases in Alberta, Canada.

Tanya Bedard1, R Brian Lowry, Barbara Sibbald, Joyce R Harder, Cynthia Trevenen, Vera Horobec, John D Dyck.   

Abstract

BACKGROUND: Congenital heart defects (CHDs) are the most common type of congenital anomaly. The precise etiology is unknown and the development of successful primary prevention strategies is challenging. Folic acid may have a protective role; however published results have been inconsistent. This study examines the impact of mandatory folic acid fortification (FAF) on the prevalence of CHDs.
METHODS: CHD cases were ascertained using the Alberta Congenital Anomalies Surveillance System, Pediatric Cardiology Clinics, Pathology, and hospital records. The birth prevalence and odds ratios (OR) of isolated CHD cases (i.e., without noncardiac anomalies) were calculated comparing pre-FAF (1995-1997) with post-FAF (1999-2002).
RESULTS: The prevalence of isolated CHD cases remained relatively unchanged when pre-FAF (9.34, 95% confidence interval [CI] 8.79-9.92) was compared with post-FAF (9.41, 95% CI, 8.93-9.91). Left ventricular outflow tract obstruction (LVOTO) decreased post-FAF (OR, 0.76; 95% CI, 0.61-0.94). Coarctation of the aorta contributed to this decline (OR, 0.55; 95% CI, 0.32-0.92). Atrial septal defect (ASD) (OR, 1.42; 95% CI, 1.13-1.80) and ASD with ventricular septal defect (OR, 1.52; 95% CI, 1.10-2.10) increased post-FAF. The remaining types of CHDs were unchanged.
CONCLUSION: FAF alone does not have an impact on the prevalence of CHDs as a group and the majority of selected types of CHDs in Alberta. The decrease in LVOTO, particularly coarctation of the aorta, may be due to FAF or other environmental factors. The increase in ASD and ASD with ventricular septal defect may reflect an increase in diagnosis and ascertainment.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Alberta; congenital heart defect; folic acid fortification; prevention; public health

Mesh:

Substances:

Year:  2013        PMID: 23913528     DOI: 10.1002/bdra.23162

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  9 in total

1.  Analyses of trends in prevalence of congenital heart defects and folic acid supplementation.

Authors:  Aimee S Parnell; Adolfo Correa
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 2.  Folate supplementation for prevention of congenital heart defects and low birth weight: an update.

Authors:  Rima Obeid; Wolfgang Holzgreve; Klaus Pietrzik
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

Review 3.  Folic acid supplementation in pregnancy and implications in health and disease.

Authors:  Subit Barua; Salomon Kuizon; Mohammed A Junaid
Journal:  J Biomed Sci       Date:  2014-08-19       Impact factor: 8.410

4.  Congenital anomalies prevalence in Addis Ababa and the Amhara region, Ethiopia: a descriptive cross-sectional study.

Authors:  Molla Taye; Mekbeb Afework; Wondwossen Fantaye; Ermias Diro; Alemayehu Worku
Journal:  BMC Pediatr       Date:  2019-07-11       Impact factor: 2.125

5.  First-Trimester Maternal Folic Acid Supplementation Reduced Risks of Severe and Most Congenital Heart Diseases in Offspring: A Large Case-Control Study.

Authors:  Yanji Qu; Shao Lin; Jian Zhuang; Michael S Bloom; Maggie Smith; Zhiqiang Nie; Jinzhuang Mai; Yanqiu Ou; Yong Wu; Xiangmin Gao; Hongzhuan Tan; Xiaoqing Liu
Journal:  J Am Heart Assoc       Date:  2020-07-02       Impact factor: 5.501

6.  Evaluation of the association between maternal folic acid supplementation and the risk of congenital heart disease: a systematic review and meta-analysis.

Authors:  Zhengpei Cheng; Rui Gu; Zenglin Lian; Harvest F Gu
Journal:  Nutr J       Date:  2022-03-26       Impact factor: 3.271

Review 7.  Neuroplacentology in congenital heart disease: placental connections to neurodevelopmental outcomes.

Authors:  Rachel L Leon; Imran N Mir; Christina L Herrera; Kavita Sharma; Catherine Y Spong; Diane M Twickler; Lina F Chalak
Journal:  Pediatr Res       Date:  2021-04-16       Impact factor: 3.953

Review 8.  Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports.

Authors:  Jennita Reefhuis; Owen Devine; Jan M Friedman; Carol Louik; Margaret A Honein
Journal:  BMJ       Date:  2015-07-08

9.  Methods to estimate access to care and the effect of interventions on the outcomes of congenital disorders.

Authors:  Hannah Blencowe; Sowmiya Moorthie; Matthew W Darlison; Stephen Gibbons; Bernadette Modell
Journal:  J Community Genet       Date:  2018-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.